EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PCK1 and SLC22A2 gene variants associated with response to metformin treatment in type 2 diabetes

Sophie St-Amour, Laurence Tessier, Janie Harnois, Catherine Allard iD, Alexandre Lavoie, Philippe Caron, Luigi Bouchard, Patrice Perron, Karine Tremblay iD

PLOS ONE · 10.02.2025 · 20 (2) · e0305511

DOI: 10.1371/journal.pone.0305511 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 10.02.2025. Verfasst von Sophie St-Amour und 8 weiteren Autor:innen. Beteiligte Einrichtung: Research Center, Centre intégré universitaire de santé et de services sociaux du Saguenay-Lac-Saint-Jean, Saguenay, Quebec, Canada. Hauptthemen laut MEDLINE: Metformin, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Organic Cation Transporter 2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Diabète Québec, Fonds de Recherche du Québec - Santé, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 2 diabetes (T2D) is a chronic disorder affecting 462 million worldwide, often managed with metformin as first-line treatment. However, metformin’s response varies among individuals, including up to 30% experiencing serious adverse drug reactions (ADRs) and 20-50% inefficacy. These differences may be due to various factors, including pharmacogenetic (PGx) variants. The PGx variants documented so far could affect both the safety and efficacy of metformin, but due to a lack of replication studies, none reached the clinical evidence-level needed to be used as a predictive marker for treatment response. Therefore, this study aims to evaluate the association between the presence of candidate PGx variants and metformin response in T2D subjects. We conducted an association study involving 108 T2D participants currently or previously treated with metformin. A characterization of their therapeutic response was carried out through questionnaires and pharmacological profile reviews. DNA samples were collected during their single visit to perform genotyping of 24 selected candidate PGx variants. Association analyses between candidate PGx variants and metformin response were performed. Among the subjects included in the analyses (n = 84), 25% were non-responders, and 58% experienced ADRs. At the time of study enrollment, 93.9% of non-responders continued to use metformin. The odds of being a non-responder to metformin are 5.6 times higher for homozygous carriers of the alternative allele of a variant within the PCK1 gene (rs4810083) compared to the other genotypes (95% interval confidence [1.9–16.6]). Two variants in perfect linkage disequilibrium within the SLC22A2 gene (rs316019 and rs316009) were associated with increase odds of having ADRs, where homozygous genotype carriers are 7.3 times more likely to have ADRs presentation (95% interval confidence [1.85–29.01]). This study identified associations between PCK1 and SLC22A2 candidate PGx variants and metformin response in T2D treatment. Additional genetic and functional studies are necessary to elucidate the variants’ impact in metformin’s pharmacological mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminDiabetes Mellitus, Type 2Hypoglycemic AgentsOrganic Cation Transporter 2Intracellular Signaling Peptides and ProteinsHumansFemaleMaleMiddle AgedPolymorphism, Single NucleotideAgedGenotypePhosphoenolpyruvate Carboxykinase (GTP)

Substanzen

MetforminHypoglycemic AgentsOrganic Cation Transporter 2SLC22A2 protein, humanPCK1 protein, humanIntracellular Signaling Peptides and ProteinsPhosphoenolpyruvate Carboxykinase (GTP)

Autor:innen und Institutionen

  • Research Center, Centre intégré universitaire de santé et de services sociaux du Saguenay-Lac-Saint-Jean, Saguenay, Quebec, Canada.
  • Department of Pharmacology-physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Saguenay, Quebec, Canada.
  • Research Center, Centre hospitalier universitaire de Sherbrooke, Université de Sherbrooke, Quebec, Canada.
  • Unité de Recherche Clinique et Epidemiologique, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada.
  • Pharmacy Department, Centre intégré universitaire de santé et services sociaux du Saguenay-Lac-Saint-Jean, Saguenay, Quebec, Canada.
  • Endocrinology Division, Centre intégré universitaire de santé et de services sociaux du Saguenay-Lac-Saint-Jean, Saguenay, Quebec, Canada.

ORCID-Profile: Catherine Allard, Karine Tremblay

Förderung

  • Diabète Québec
  • Fonds de Recherche du Québec - Santé
  • Canadian Institutes of Health Research
  • Faculté de médecine et des sciences de la santé, Université de Sherbrooke

Zitieren

APA

St-Amour, S., Tessier, L., Harnois, J., Allard, C., Lavoie, A., Caron, P., Bouchard, L., Perron, P., & Tremblay, K. (2025). PCK1 and SLC22A2 gene variants associated with response to metformin treatment in type 2 diabetes. PLOS ONE, 20(2), e0305511. https://doi.org/10.1371/journal.pone.0305511

Vancouver

St-Amour S, Tessier L, Harnois J, Allard C, Lavoie A, Caron P, et al. PCK1 and SLC22A2 gene variants associated with response to metformin treatment in type 2 diabetes. PLOS ONE. 2025;20(2):e0305511. doi:10.1371/journal.pone.0305511

BibTeX
@article{StAmour2025,
  author = {St-Amour, Sophie and Tessier, Laurence and Harnois, Janie and Allard, Catherine and Lavoie, Alexandre and Caron, Philippe and Bouchard, Luigi and Perron, Patrice and Tremblay, Karine},
  title = {PCK1 and SLC22A2 gene variants associated with response to metformin treatment in type 2 diabetes},
  journal = {PLOS ONE},
  year = {2025},
  volume = {20},
  number = {2},
  pages = {e0305511},
  doi = {10.1371/journal.pone.0305511}
}
Kostenlos starten →